Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk (DaNGER)

NCT05402579 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT05402579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05402579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk (DaNGER)
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Observational
Overall status
Completed
Start date
July 29, 2022
Completion date
January 20, 2025
Enrollment
63 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes type 2, diabetic ketoacidosis, dka